| Anjelica D Pearson, | |
|
2000 Olathe Ste 4001, Kansas City, KS 66160-8505 | |
| (913) 588-5730 | |
| Not Available |
| Full Name | Anjelica D Pearson |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 2000 Olathe Ste 4001, Kansas City, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629717046 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Primary |
| Provider Name | Kansas University Physicians, Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Expectant mothers who gain large amounts of weight tend to give birth to heavier infants who are at higher risk for obesity later in life. But it's never been proven that this tendency results from the weight gain itself, rather than genetic or other factors that mother and baby share. A large population-based study from Children's Hospital Boston, looking at two or more pregnancies in the same mother, now provides evidence that excess maternal weight gain is a strong, independent predictor of high birth weight.
Today, the International Osteoporosis Foundation (IOF) released a new report, revealing approximately 80 percent of patients treated in clinics or hospitals following a fracture are not screened for osteoporosis or risk of future falls. Left untreated, these patients are at high risk of suffering secondary fractures and facing a future of pain, disfigurement, long-term disability and even early death.
There is a sharp contrast between people's positive attitudes towards growing old and their preparedness according to the results of a new international survey, Bupa Health Pulse 2010, published today by Bupa Health Dialog.
Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anjelica D Pearson, 2000 Olathe Ste 4001, Kansas City, KS 66160-1619 Ph: () - | Anjelica D Pearson, 2000 Olathe Ste 4001, Kansas City, KS 66160-8505 Ph: (913) 588-5730 |
News Archive
Expectant mothers who gain large amounts of weight tend to give birth to heavier infants who are at higher risk for obesity later in life. But it's never been proven that this tendency results from the weight gain itself, rather than genetic or other factors that mother and baby share. A large population-based study from Children's Hospital Boston, looking at two or more pregnancies in the same mother, now provides evidence that excess maternal weight gain is a strong, independent predictor of high birth weight.
Today, the International Osteoporosis Foundation (IOF) released a new report, revealing approximately 80 percent of patients treated in clinics or hospitals following a fracture are not screened for osteoporosis or risk of future falls. Left untreated, these patients are at high risk of suffering secondary fractures and facing a future of pain, disfigurement, long-term disability and even early death.
There is a sharp contrast between people's positive attitudes towards growing old and their preparedness according to the results of a new international survey, Bupa Health Pulse 2010, published today by Bupa Health Dialog.
Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
› Verified 6 days ago
Dr. Nicole M Leonard, AUD CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd # Ms 3010, Kansas City, KS 66103 Phone: 913-588-6745 Fax: 913-588-4676 | |
Lindsay Lad, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-6701 | |
Madison Marie Braun, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 4000 Cambridge St, Kansas City, KS 66160 Phone: 135-886-7019 | |
Mallory Miller, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2000 Olathe, Kansas City, KS 66160 Phone: 913-588-5730 | |
Cole Campbell, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-4375 | |
Judith E Widen, PHD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd Msc 4043, 2032 School Of Nursing, Kansas City, KS 66160 Phone: 866-249-9736 |